entertainment -WSS

entertainment

author：focus 2025-09-06 04:50:51 - browse：6132

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Mindstrong's demise and the future of mental health care

WSS

Why do women spend more than men on medical expenses?

Covid vaccines: Private market messier than government rollout

Scientists grapple with ethics of stem cell research

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Menendez indictment could see pharma lose a key ally

5 dead in mass shooting on Caribbean island of St. Vincent: Police

explore

entertainment

focus

Tori Bowie and the unacceptable rates of Black maternal death

Data show record exodus of life scientists from academia

As demand for Covid shots wanes, Moderna seeks its next success

Would Medicare drug price negotiations stall in a shutdown?

Apple is now the first public company to be valued at $3 trillion

Medicaid, Medicare dual

Guidelines to prevent youth baseball injuries need more muscle

Sudafed saga points to U.S. issues with evaluating older drugs

Guidelines to prevent youth baseball injuries need more muscle

A new ‘biological computer' targets cancer while sparing healthy cells

entertainment

There’s a way to spot data fakery. All journals should be using it

Medicaid, Medicare dual

Why do women spend more than men on medical expenses?

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Data show record exodus of life scientists from academia

Sudafed saga points to U.S. issues with evaluating older drugs

hotspot

explore

knowledge

hotspot